Hyperbaric oxygen improves tumor radiation response significantly more than carbogen/nicotinamide
- PMID: 9189170
Hyperbaric oxygen improves tumor radiation response significantly more than carbogen/nicotinamide
Abstract
This laboratory previously demonstrated that hyperbaric oxygen and hyperbaric carbogen improved oxygenation in the R3230Ac tumor, but normobaric 100% O2 and carbogen did not. The current study assessed tumor growth after exposure to radiation plus either hyperbaric oxygen, carbogen or carbogen/nicotinamide and the relationship between pretreatment tumor oxygenation and growth time. R3230Ac carcinomas were grown in the flanks of F344 rats. Animals were randomized to one of seven radiation treatment groups: sham irradiation or irradiation plus room air, hyperbaric oxygen (100% O2/3 atmospheres), nicotinamide (0.3 mg/g intraperitoneally 20 min before irradiation), carbogen, carbogen/nicotinamide or hyperbaric oxygen/nicotinamide. Tumors received 20 Gy in a single dose. Median growth times were 6, 18, 18, 20, 22, 28 and 27 days for controls and irradiation plus room air, carbogen, nicotinamide, carbogen/nicotinamide, hyperbaric oxygen and hyperbaric oxygen/nicotinamide, respectively. Irradiation with hyperbaric oxygen, hyperbaric oxygen/ nicotinamide and carbogen/nicotinamide increased growth time (P < 0.001, P < 0.001 and P = 0.003, respectively) relative to room air. Hyperbaric oxygen was significantly more effective than carbogen/nicotinamide (P = 0.001). Growth times for all tumors exposed to hyperbaric oxygen were longer than those of the most fully oxygenated tumors (no baseline pO2 values < 10 mm Hg) not exposed to hyperbaric oxygen (P < 0.001). These results suggest that hyperbaric oxygen may improve radiation response by additional mechanisms separate from overcoming the oxygen effect.
Comment in
-
Is hyperbaric oxygen more effective than carbogen/nicotinamide in tumor radiation response?Radiat Res. 1997 Nov;148(5):523-5. Radiat Res. 1997. PMID: 9355875 No abstract available.
-
Comments on hyperbaric oxygen and carbogen/nicotinamide with fractionated radiation.Radiat Res. 1997 Nov;148(5):526-7. Radiat Res. 1997. PMID: 9355876 No abstract available.
Similar articles
-
Preclinical studies on how to deal with patient intolerance to nicotinamide and carbogen.Radiother Oncol. 2004 Mar;70(3):301-9. doi: 10.1016/j.radonc.2004.01.017. Radiother Oncol. 2004. PMID: 15064017
-
Comparison of the effectiveness of tirapazamine and carbogen with nicotinamide in enhancing the response of a human tumor xenograft to fractionated irradiation.Radiat Oncol Investig. 1999;7(3):163-9. doi: 10.1002/(SICI)1520-6823(1999)7:3<163::AID-ROI5>3.0.CO;2-M. Radiat Oncol Investig. 1999. PMID: 10406058
-
Hypoxic radiosensitizers in radical radiotherapy for patients with bladder carcinoma: hyperbaric oxygen, misonidazole, and accelerated radiotherapy, carbogen, and nicotinamide.Cancer. 1999 Oct 1;86(7):1322-8. Cancer. 1999. PMID: 10506720 Clinical Trial.
-
A therapeutic benefit from combining normobaric carbogen or oxygen with nicotinamide in fractionated X-ray treatments.Radiother Oncol. 1991 Oct;22(2):81-91. doi: 10.1016/0167-8140(91)90002-x. Radiother Oncol. 1991. PMID: 1835542 Review.
-
Clinical results of hypoxic cell radiosensitisation from hyperbaric oxygen to accelerated radiotherapy, carbogen and nicotinamide.Br J Cancer Suppl. 1996 Jul;27:S271-8. Br J Cancer Suppl. 1996. PMID: 8763896 Free PMC article. Review.
Cited by
-
Hypoxia: syndicating triple negative breast cancer against various therapeutic regimens.Front Oncol. 2023 Jul 10;13:1199105. doi: 10.3389/fonc.2023.1199105. eCollection 2023. Front Oncol. 2023. PMID: 37492478 Free PMC article. Review.
-
(18)F-misonidazole PET imaging of hypoxia in micrometastases and macroscopic xenografts of human non-small cell lung cancer: a correlation with autoradiography and histological findings.Am J Nucl Med Mol Imaging. 2013;3(2):142-53. Epub 2013 Mar 8. Am J Nucl Med Mol Imaging. 2013. PMID: 23526377 Free PMC article.
-
The effects of hyperoxic and hypercarbic gases on tumour blood flow.Br J Cancer. 1999 Apr;80(1-2):117-26. doi: 10.1038/sj.bjc.6690330. Br J Cancer. 1999. PMID: 10389987 Free PMC article.
-
Efficacy and safety of recombinant human endostatin combined with radiotherapy or chemoradiotherapy in patients with locally advanced non-small cell lung cancer: a pooled analysis.Radiat Oncol. 2020 Aug 24;15(1):205. doi: 10.1186/s13014-020-01646-9. Radiat Oncol. 2020. PMID: 32831120 Free PMC article.
-
Temporal changes in tumor oxygenation and perfusion upon normo- and hyperbaric inspiratory hyperoxia.Strahlenther Onkol. 2016 Mar;192(3):174-81. doi: 10.1007/s00066-015-0916-1. Epub 2015 Oct 26. Strahlenther Onkol. 2016. PMID: 26501141